
Hologic Inc
NASDAQ:HOLX

HOLX's latest stock split occurred on Apr 3, 2008
The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.
Before the split, HOLX traded at 58.99 per share. Afterward, the share price was about 30.03.
The adjusted shares began trading on Apr 3, 2008. This was HOLX's 3rd stock split, following the previous one in Dec 1, 2005.
Hologic Inc
Glance View
Hologic Inc., headquartered in Marlborough, Massachusetts, crafts a narrative deeply intertwined with the vital mission of women's health. Established in 1985, the company has grown into a prominent player in the medical device and diagnostics realm. Hologic’s success is anchored in its core business sectors: Breast & Skeletal Health, Diagnostic Solutions, GYN Surgical, and Medical Aesthetics. The cornerstone of this expansive operation is innovation, driving the development of advanced technologies like 3D mammography systems that revolutionize breast cancer detection. This strategic focus on high-value diagnostics and medical equipment allows Hologic to capture significant market share, ensuring a steady revenue stream from both capital equipment sales and ongoing service and maintenance contracts. Beyond its robust presence in imaging and diagnostics, Hologic amplifies its influence through a comprehensive array of solutions for early stage disease detection and treatment. Their Diagnostic Solutions arm, particularly strengthened by molecular diagnostic tests, is a response to the increasing global demand for rapid and accurate testing solutions—a need only intensified by recent global health challenges. These products not only provide critical tools for healthcare professionals but also secure recurring income for Hologic through the sale of consumables and tests. By embedding itself in the cycles of medical advancements and enhancing the standard of care, Hologic generates sustainable growth and remains a crucial ally in both public and specialized health sectors. The company’s blend of technology-driven products and strategic agility enables it to navigate dynamic markets while maintaining a resolute focus on improving health outcomes around the world.
